Amniotic Membrane Powder in Hydrogel Scaffolds for Cell-Free Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for extensive burns and full-thickness skin wounds, such as autologous split-thickness skin grafts and allografts, are limited by donor site availability and require immunosuppressive drugs, while non-cellular dermal substitutes are costly and yield poor cosmetic outcomes.
Innovation Solution
A composition comprising amniotic membrane powder, optionally incorporated into a hydrogel scaffold, is applied to wounds to promote healing and tissue regeneration, minimizing inflammatory responses and enhancing tissue regeneration without the need for cellular components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous split-thickness skin grafts are used, then wound healing is achieved, but donor site availability is limited
Solution Approach 1:
The patent uses amniotic membrane as a substitute that copies the functional properties of skin without requiring donor tissue. The amniotic membrane contains extracellular matrix components (collagen, elastin, glycosaminoglycans) and growth factors that mimic skin structure and promote wound healing, eliminating the need for limited donor sites while achieving comparable healing outcomes
Solution Approach 2:
The amniotic membrane is processed into a disposable powder form that can be applied to wounds without requiring precious donor tissue. This single-use approach eliminates the need for donor site harvesting and reduces the constraints of tissue availability while maintaining effective wound healing capabilities
2Reliability
If allografts are used, then wound coverage is achieved, but immunosuppressive drugs are required
Solution Approach 1:
The patent extracts and utilizes only the extracellular matrix components and bioactive molecules from amniotic membrane, excluding cellular elements that would trigger immune responses. This cell-free approach removes the immunogenic components while retaining the wound healing and tissue regeneration properties, eliminating the need for immunosuppressive therapy
Solution Approach 2:
The amniotic membrane acts as an intermediary material that provides wound coverage and promotes healing without requiring immune suppression. Its extracellular matrix components serve as a biocompatible bridge between the wound bed and healthy tissue, facilitating regeneration without triggering rejection responses that would require immunosuppressive drugs
3Ease of manufacture
If non-cellular dermal substitutes are used, then production cost is reduced, but cosmetic outcomes are poor
Solution Approach 1:
The patent creates a composite material from amniotic membrane that combines multiple extracellular matrix components (collagen, elastin, glycosaminoglycans) and growth factors in specific proportions. This composite structure mimics native skin architecture more effectively than single-material substitutes, achieving superior cosmetic outcomes while maintaining cost-effectiveness through standardized processing
Solution Approach 2:
The patent optimizes the composition parameters of the amniotic membrane powder, including protein content (30-500 mg/g), elastin content (4-100 mg/g), collagen content (10-800 mg/g), and glycosaminoglycan content (0.1-5 mg/g), to achieve optimal cosmetic outcomes. By controlling these parameters during processing, the patent improves manufacturing precision and aesthetic results while maintaining cost efficiency
4Reliability
If amniotic membrane powder with high protein content is used, then tissue regeneration is enhanced, but production complexity increases
Solution Approach 1:
The patent segments the amniotic membrane processing into distinct stages: decellularization to remove cellular material, extracellular matrix extraction to isolate bioactive components, lyophilization to preserve structure, and milling to create standardized powder. This segmentation simplifies production by breaking down complex processes into manageable steps while ensuring consistent protein content (30-500 mg/g) and bioactivity for optimal tissue regeneration
Solution Approach 2:
The patent establishes specific parameter ranges for the amniotic membrane powder to balance tissue regeneration efficacy with production feasibility: total protein (30-500 mg/g), elastin (4-100 mg/g), collagen (10-800 mg/g), and glycosaminoglycans (0.1-5 mg/g). These parameter specifications standardize the product, reducing production complexity while maintaining high regenerative capacity
Data Source
AI summary
The present invention includes compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane powder. The compositions of the present invention comprise amniotic membrane powder and a scaffold. The methods of the present invention comprises applying a composition of the present invention to a subject to induce wound healing and tissue regeneration.